|

Darolutamide 300 mg Clinical Trials

3 actively recruiting trials

Also known as: Nubeqa, Nubeqa®

Pipeline

Phase 3: 3

Top Sponsors

  • UNICANCER2
  • Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie1

Indications

  • Cancer3
  • Prostate Cancer Metastatic1
  • Prostate Cancer1
  • Prostatic Cancer, Castration-Resistant1

Other3 trials

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Phase 3
Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
Phase 3
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.